Outpace Bio Announces $144M Oversubscribed Series B Financing to Advance AI-powered Cell Therapies into Clinical Development

Globe Newswire

Outpace Bio to present new data on programmed CAR T cell candidate OPB-101 at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Globe Newswire

Outpace Bio Announces $144M Oversubscribed Series B Financing to Advance AI-powered Cell Therapies into Clinical Development

Endpoints News

With $144M Series B, Outpace Bio beats funding goal for solid tumor cell therapies

synbiobeta

AI-Driven Cell Therapy Pioneer Outpace Bio Raises $144M in Series B Funding

GeekWire

Protein design startup Outpace lands $144M to test treatments that target solid tumors

American Association for Cancer Research (AACR)

In vitro modeling of antigen-driven exhaustion in human CAR T cells

American Association for Cancer Research (AACR)

"Development of tumor-restricted IL-12 with antigen-dependent expression and localized IL-12 activity"

American Association for Cancer Research (AACR)

OPB-101: An optimized mesothelin-specific CAR T cell product expressing CD8-targeted IL-2/15 and engineered to resist T cell exhaustion